

PRESS RELEASE

Uppsala March 3, 2011

Q-Med AB (publ) applies for delisting, postpones the annual general meeting and convenes an extraordinary general meeting

Galderma's public offer for Q-Med AB (publ) ("Q-Med" or the "Company") was declared unconditional on 25 February 2011. Galderma controls more than 90 per cent of the shares in Q-Med and has requested compulsory acquisition in respect of the shares in Q-Med that Galderma does not own.

As requested by Galderma, the Board of Q-Med has convened an Extraordinary General Meeting to be held on 28 March 2011, for the purposes of, amongst other things, appointing a new board.

Further, at the proposal of Galderma the Board of Q-Med has resolved to apply for delisting of the Company's shares from NASDAQ OMX Stockholm ("NASDAQ OMX"). The last day of trading in the Company's shares on NASDAQ OMX will be announced as soon as the Company has received confirmation from NASDAQ OMX.

At the proposal of Galderma, the Board of Q-Med has also resolved to postpone the Annual General Meeting scheduled to be held on 28 April 2011. A new date for the Annual General Meeting will be set by the new Board of Q-Med after the Extraordinary General Meeting on 28 March 2011.

Uppsala March 3, 2011
The Board of Q-Med AB (publ)

Queries should be addressed to:

Alexander Kotsinas, CFO
Tel: +46 73 500 111
Carina Bolin, General Counsel
Tel: +46 70 974 9117

The information in this press release is such as that which Q-Med is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for disclosure at 7.40 p.m. on March 3, 2011.

Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta®** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
